Revenue Update on Neurocrine Biosciences(NASDAQ:NBIX)

Neurocrine Biosciences(NASDAQ:NBIX) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Feb 14, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $0.000. Analysts estimated a revenue of $4.170M. The revenues were -100% below the estimates. Earnings per share were $-0.51. The reported EPS was above estimates by 1.92%. Analysts had estimated an EPS of $-0.52.

In a different note, On Jan 27, 2017, Oppenheimer said it Upgrades its rating on Neurocrine Biosciences. The shares have been rated ‘Outperform’ by the firm.

Neurocrine Biosciences (NBIX) shares turned negative on Wednesdays trading session with the shares closing down -1.3 points or -2.96% at a volume of 8,08,594. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $44.3375. The peak price level was also seen at $44.3375 while the days lowest was $42.58. Finally the shares closed at $42.6. The 52-week high of the shares is $55.15 while the 52-week low is $32.18. According to the latest information available, the market cap of the company is $3,711 M.

Several Insider Transactions has been reported to the SEC. On Feb 8, 2017, Dimitri E. Grigoriadis (Chief Research Officer) sold 727 shares at $43.13 per share price.Also, On Feb 8, 2017, Haig P. Bozigian (Chief Development Officer) sold 963 shares at $43.14 per share price.On Feb 8, 2017, Kyle Gano (Chief Business Development Off) sold 727 shares at $43.15 per share price, according to the Form-4 filing with the securities and exchange commission.

Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.

Add Comment